ArticleJournal of ovarian research2026
Immune checkpoint inhibitors-based therapies for first-line treatment of advanced ovarian cancer with non-BRCAm/HRD-negative: a cost-effectiveness analysis.
Youwen Zhu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.